Microenvironment Molecular Targets, Istituto Nazionale Tumori-IRCCS-Fondazione "G. Pascale", Via Semmola, 80131, Naples, Italy.
Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, University of Campania "Luigi Vanvitelli", Via Vivaldi 43, 81100, Caserta, Italy.
Hepatol Int. 2024 Apr;18(2):568-581. doi: 10.1007/s12072-023-10537-6. Epub 2023 May 4.
While HCC is an inflammation-associated cancer, CRLM develops on permissive healthy liver microenvironment. To evaluate the immune aspects of these two different environments, peripheral blood-(PB), peritumoral-(PT) and tumoral tissues-(TT) from HCC and CRLM patients were evaluated.
40 HCC and 34 CRLM were enrolled and freshly TT, PT and PB were collected at the surgery. PB-, PT- and TT-derived CD4CD25 Tregs, M/PMN-MDSC and PB-derived CD4CD25 T-effector cells (Teffs) were isolated and characterized. Tregs' function was also evaluated in the presence of the CXCR4 inhibitor, peptide-R29, AMD3100 or anti-PD1. RNA was extracted from PB/PT/TT tissues and tested for FOXP3, CXCL12, CXCR4, CCL5, IL-15, CXCL5, Arg-1, N-cad, Vim, CXCL8, TGFβ and VEGF-A expression.
In HCC/CRLM-PB, higher number of functional Tregs, CD4CD25FOXP3 was detected, although PB-HCC Tregs exert a more suppressive function as compared to CRLM Tregs. In HCC/CRLM-TT, Tregs were highly represented with activated/ENTPD-1Tregs prevalent in HCC. As compared to CRLM, HCC overexpressed CXCR4 and N-cadherin/vimentin in a contest rich in arginase and CCL5. Monocytic MDSCs were highly represented in HCC/CRLM, while high polymorphonuclear MDSCs were detected only in HCC. Interestingly, the function of CXCR4-PB-Tregs was impaired in HCC/CRLM by the CXCR4 inhibitor R29.
In HCC and CRLM, peripheral blood, peritumoral and tumoral tissues Tregs are highly represented and functional. Nevertheless, HCC displays a more immunosuppressive TME due to Tregs, MDSCs, intrinsic tumor features (CXCR4, CCL5, arginase) and the contest in which it develops. As CXCR4 is overexpressed in HCC/CRLM tumor/TME cells, CXCR4 inhibitors may be considered for double hit therapy in liver cancer patients.
尽管 HCC 是一种与炎症相关的癌症,但 CRLM 是在允许的健康肝脏微环境中发展的。为了评估这两种不同环境的免疫方面,评估了 HCC 和 CRLM 患者的外周血(PB)、肿瘤周围(PT)和肿瘤组织(TT)。
纳入 40 例 HCC 和 34 例 CRLM 患者,在手术时采集新鲜 TT、PT 和 PB。分离并鉴定 PB、PT 和 TT 来源的 CD4CD25 Treg、M/PMN-MDSC 和 PB 来源的 CD4CD25 T 效应细胞(Teffs)。还在 CXCR4 抑制剂肽-R29、AMD3100 或抗 PD1 的存在下评估 Treg 的功能。从 PB/PT/TT 组织中提取 RNA,并检测 FOXP3、CXCL12、CXCR4、CCL5、IL-15、CXCL5、Arg-1、N-cad、Vim、CXCL8、TGFβ 和 VEGF-A 的表达。
在 HCC/CRLM-PB 中,检测到更多数量的功能性 Treg,CD4CD25FOXP3,尽管与 CRLM Treg 相比,PB-HCC Treg 发挥了更强的抑制功能。在 HCC/CRLM-TT 中,Treg 高度表达,HCC 中存在活化/ENTPD-1Treg。与 CRLM 相比,HCC 在富含精氨酸酶和 CCL5 的环境中过度表达 CXCR4 和 N-钙粘蛋白/波形蛋白。单核细胞 MDSC 在 HCC/CRLM 中高度表达,而高多形核 MDSC 仅在 HCC 中检测到。有趣的是,CXCR4 抑制剂 R29 可损害 HCC/CRLM 中 PB-Tregs 的功能。
在 HCC 和 CRLM 中,外周血、肿瘤周围和肿瘤组织 Treg 高度表达并具有功能。然而,由于 Treg、MDSC、固有肿瘤特征(CXCR4、CCL5、精氨酸酶)以及肿瘤发生的环境,HCC 显示出更具免疫抑制性的 TME。由于 HCC/CRLM 肿瘤/TME 细胞中过度表达 CXCR4,因此 CXCR4 抑制剂可考虑用于肝癌患者的双重打击治疗。